NovoCure Limited (NASDAQ:NVCR – Get Free Report) has been given a consensus rating of “Moderate Buy” by the nine ratings firms that are presently covering the company, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12 […]